<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~49,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging</td>
</tr>
</table>
The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~49,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging</td>
</tr>
</table>
The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.
The institution's location in Madison, Wisconsin, has fostered a unique research environment that combines access to diverse patient populations, strong academic resources, and a collaborative culture that has produced landmark discoveries in neurodegenerative disease research. The Wisconsin Alzheimer's Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer Prevention (WRAP) represent some of the most influential programs in the field.
The University of Wisconsin-Madison was founded in 1848 as the state's land-grant university. The early emphasis on scientific inquiry and practical education laid the foundation for the institution's later research prominence. The Department of Neurology was established in the mid-20th century, marking the beginning of systematic neuroscience research.
Throughout the latter half of the 20th century, UW-Madison built its neuroscience research capabilities through strategic hiring and infrastructure investments. Key developments include:
The Wisconsin Alzheimer's Disease Research Center (WADRC) was established in 2009 with funding from the National Institute on Aging, becoming one of 33 NIH-funded Alzheimer's Disease Research Centers. The center has made seminal contributions to understanding preclinical Alzheimer's disease and identifying biomarkers that enable early detection[@johnson2018].
The WADRC's mission encompasses:
UW-Madison's research facilities are among the most advanced in the world. The campus features purpose-built research space designed for interdisciplinary collaboration.
The WADRC occupies dedicated research space on the university campus, housing:
The Waisman Center is one of the nation's premier centers for developmental disabilities and neurodegenerative disease research. Established in 1973, it provides:
The Center for Neurodegeneration and Repair (CNR) brings together researchers from multiple departments to study:
| Center | Focus | Director |
|--------|-------|----------|
| Wisconsin Alzheimer's Disease Research Center | AD biomarkers and clinical research | Dr. Sterling C. Johnson |
| Wisconsin Registry for Alzheimer Prevention | Preclinical AD and lifestyle factors | Dr. Mark A. Sager |
| Center for Neurodegeneration and Repair | Multiple neurodegenerative diseases | Dr. Matthew R. Anderson |
| Waisman Center | Neurodevelopment and neurodegeneration | Dr. Albee Messing |
| Center for Sleep and Consciousness | Sleep and brain health | Dr. Giulio Tononi |
The Alzheimer's disease research program at UW-Madison represents one of the nation's most comprehensive efforts to understand preclinical Alzheimer's disease and develop early intervention strategies. The program's focus on early detection has yielded critical insights into disease progression and risk factors["@johnson2020"].
Researchers at UW-Madison have made substantial contributions to biomarker research:
Cerebrospinal Fluid Biomarkers
The program has identified multiple modifiable risk factors:
The clinical research program encompasses:
The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer's disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years[@sager2019].
WRAP has contributed to major findings including:
Research from UW-Madison has appeared in leading journals:
The Parkinson's disease research program at UW-Madison has developed into a comprehensive effort spanning basic science, clinical research, and therapeutic development. The program benefits from the institution's expertise in protein aggregation, dopamine biology, and neuroimaging.
Researchers study the normal function and pathological aggregation of alpha-synuclein:
The program investigates dopamine neuron biology:
The clinical research program includes:
UW-Madison researchers have contributed substantially to understanding non-motor symptoms:
| Researcher | Position | Focus Area |
|------------|----------|------------|
| Dr. Sterling C. Johnson | Professor, WADRC Director | Preclinical AD biomarkers, neuroimaging |
| Dr. Barbara B. Bendlin | Associate Professor | Lifestyle factors, biomarkers, neuroimaging |
| Dr. Matthew R. Anderson | Chair of Neurology | Parkinson's disease, movement disorders |
| Dr. Mark A. Sager | Professor | WRAP, cognitive aging |
| Dr. Sanjay Asthana | Professor | AD clinical trials, biomarkers |
| Dr. Joseph R. W. Ryman | Associate Professor | Alpha-synuclein biology |
Dr. Sterling Johnson leads the WADRC and has been instrumental in characterizing preclinical Alzheimer's disease through the WRAP cohort. His research has focused on identifying biomarker changes that occur decades before clinical symptoms appear. The Johnson laboratory has published extensively on the relationship between amyloid and tau pathology and cognitive decline, demonstrating that biomarker changes can predict future cognitive impairment even in cognitively normal individuals[@johnson2018][@johnson2020]. Current research explores multi-modal biomarker approaches combining imaging, CSF, and blood-based measures.
Dr. Bendlin's research examines how lifestyle factors influence Alzheimer's disease biomarkers and risk. Her work has shown that cardiovascular health, exercise, diet, and other modifiable factors can influence brain aging and Alzheimer's disease pathology[@bendlin2019][@koscik2021]. The Bendlin laboratory uses neuroimaging and biomarker approaches to understand how lifestyle interventions may protect against neurodegeneration.
Dr. Anderson chairs the Department of Neurology and leads the Parkinson's disease research program. His research focuses on understanding the mechanisms of dopaminergic neuron degeneration and developing neuroprotective strategies. The Anderson laboratory investigates alpha-synuclein biology, mitochondrial dysfunction, and neuroinflammation in Parkinson's disease pathogenesis.
The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer's disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years[@sager2019].
WRAP participants are recruited from throughout Wisconsin, with an emphasis on including individuals with a family history of Alzheimer's disease. The cohort includes:
WRAP has contributed to major findings including:
WRAP researchers have made significant contributions to biomarker science:
Amyloid PET Imaging: Longitudinal amyloid PET imaging has characterized the temporal relationship between amyloid deposition and downstream tau pathology and cognitive decline[@cody2023]. Studies show that amyloid accumulation begins decades before symptoms and follows a predictable trajectory.
CSF Biomarkers: WRAP has contributed to understanding how CSF biomarkers change in preclinical AD, including amyloid, tau, and neurofilament light chain measurements[@bendlin2019]. These studies have informed biomarker cutoff values and diagnostic criteria.
Blood Biomarkers: UW-Madison researchers have been at the forefront of developing blood-based biomarkers, comparing plasma and CSF measures and validating ultra-sensitive assays for clinical use.
UW-Madison offers comprehensive neuroscience training:
The institution supports postdoctoral researchers through:
UW-Madison maintains collaborations with leading institutions:
The institution participates in national and international networks:
UW-Madison collaborates with pharmaceutical companies:
UW-Madison researchers have made significant contributions:
The institution's research productivity includes:
UW-Madison has identified key research priorities:
UW-Madison provides specialized clinics:
UW-Madison maintains an active clinical trials program for neurodegenerative diseases, participating in trials across all phases of drug development.
The WADRC and Memory Disorders Clinic participate in numerous Alzheimer's disease clinical trials:
Disease-Modifying Therapies: UW-Madison has been a key site for anti-amyloid antibody trials, including lecanemab and donanemab studies. The institution contributed significantly to the CLARITY-AD and TRAILBLAZER trials, evaluating whether amyloid removal translates to clinical benefit.
Tau-Targeting Therapies: The institution participates in trials of anti-tau antibodies and small molecule inhibitors targeting tau aggregation. These studies examine whether interrupting tau propagation can slow disease progression.
Prevention Trials: Given the focus on preclinical AD through WRAP, UW-Madison is well-positioned for prevention trials in at-risk individuals. Studies examine whether interventions before symptom onset can delay or prevent cognitive decline.
Neuroprotective Strategies: Trials testing compounds aimed at protecting neurons from various injury pathways, including oxidative stress, excitotoxicity, and neuroinflammation.
The Movement Disorders program conducts clinical trials including:
Alpha-Synuclein-Targeting Therapies: Participation in trials of monoclonal antibodies targeting aggregated alpha-synuclein, including PRX002 and related agents. These therapies aim to reduce pathological protein burden and slow disease progression.
LRRK2 Inhibitors: As LRRK2 is one of the most common genetic causes of PD, UW-Madison participates in trials of LRRK2 kinase inhibitors aimed at developing disease-modifying treatments for genetic and idiopathic PD.
Deep Brain Stimulation: Studies optimizing stimulation parameters, exploring novel targets, and evaluating closed-loop stimulation approaches that respond to patient symptoms in real-time.
Symptomatic Therapies: Trials of novel dopaminergic agents, including extended-release formulations and combination therapies for motor and non-motor symptoms.
UW-Madison provides comprehensive infrastructure for clinical research:
UW-Madison works with patient organizations:
The institution provides: